Takeda Pharmaceutical Co. and Eli Lilly and Co. lost a bid to have a judge throw out a combined $9 billion punitive-damage award over claims the drugmakers hid the cancer risks of their Actos diabetes medicine.
The Indiana Blood Center is set to lose more than one-third of its revenue early next year, as three hospital systems bolt for cheaper prices offered by the American Red Cross.
Franciscan Alliance, which operates three hospitals in the Indianapolis area, is seeing fewer patients this year but is making more money due to expense cuts.
Rural/Metro Corp. says the changing health care landscape and the challenges of covering rural communities are forcing it to end its area ambulance services. It’s also closing a billing operations center in Indianapolis.
Final approval could be delayed until mid-2016 due to a claim of patent infringement by drugmaker Sanofi.
A subsidiary of Dublin, Ohio-based Cardinal Health Inc. is seeking tax breaks from the city of Indianapolis to help it open a $14.4 million local drug-production facility that would employ 85 workers by 2017.
The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020.
The plant closure will affect 23 plant employees, all of whom will be offered comparable positions at a Lilly plant near Clinton that employs about 500 workers.
Bloomington’s Monroe Hospital, which has had a close relationship with Indianapolis-based St. Vincent Health, filed for bankruptcy reorganization on Friday and plans to sell its business to a Canadian operator.
The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes who also are trying to control their condition with diet and exercise.
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
In a wide-ranging interview, WellPoint Inc. CEO Joseph Swedish says adapting to technology is a top priority as he leads the nation's second largest health insurer.
Global firm Covidien LP plans to consolidate U.S. operations for servicing its medical devices in central Indiana, renovating its existing 70,000-square-foot facility in the process.
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
Strand Diagnostics LLC’s Know Error test uses DNA analysis to make sure a tissue sample that has been declared cancerous does, indeed, belong to the patient doctors think it does. But Strand is having trouble convincing Medicare that the test is medically necessary.
Indiana University Health wants to merge two of its big downtown hospitals—University and Methodist—into one location, meaning either one or both would close or be converted to another use.
Fishers will forgive as much as $300,000 in development fees to get a $17.6 million expansion project started by Aug. 1.
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
The decision to collect cases before one court comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
A bill proposed by four Senate Republicans would give veterans more flexibility to see a private doctor if they are forced to wait too long for an appointment at a Veterans Affairs hospital or clinic.
